INVESTING IN BIOTECH FUTURE
WonderBank Holdings leverages a proprietary biobank of 65 HLA-homozygous “super donor” stem cell lines that enable standardized, off-the-shelf therapies matched to more than 90% of U.S. and European patients. These stem cells can be differentiated into most cell types, supporting scalable, tissue-matched therapies without gene editing or extensive immunosuppression. Centralized manufacturing of cryopreserved products provides immediate availability, operational efficiency, and broad deployment across indications.
PORTFOLIO ENTITIES
AlloMatch
AlloMatch is advancing an off-the-shelf CAR T platform derived from the biobank, offering HLA-matched therapies for over 90% of patients. This approach removes the need for individualized manufacturing, reduces costs by up to 90% compared with autologous CAR Ts, and ensures consistent, scalable dosing.
GlucoStem
GlucoStem is targeting diabetes with stem cell-derived, HLA-matched islets designed to restore physiological insulin production while overcoming immune rejection and donor limitations. ARPA-H-funded infrastructure enables large-scale manufacturing, with preclinical studies demonstrating complete disease reversal and a market opportunity exceeding $15B by 2030.
NeuropathBio
NeuropathBio addresses neuropathic pain with allogeneic iPSC-derived mesenchymal stem cells that repair nerve damage and modulate immune responses. Off-the-shelf dosing from the biobank enables rapid access and scalable production. Preclinical evidence shows structural recovery and durable symptom improvement, positioning the therapy for impact in a $3B market.
OsteoCare
OsteoCare is developing an injectable, HLA-matched chondrocyte therapy to regenerate knee cartilage in osteoarthritis patients, avoiding joint replacement and custom manufacturing. Supported by strong IP, GMP readiness, ARPA-H partnership, and leading research collaborators, OsteoCare holds a first-mover advantage in a $1B+ market.